Biotech Insider Buying: April 2026 Roundup

Over the last 30 days, 20 insider purchases were filed across 10 biotech companies. These are open-market buys only — we filter out routine 10b5-1 plan transactions, option exercises, and other noise using AI classification. Insider purchases in biotech small-caps carry more signal value than in large-caps, because the information asymmetry is higher. A CEO buying shares 3 weeks before a PDUFA date is making a bet with their own money — and research shows these "opportunistic" purchases predict abnormal returns.

- [WVE](/company/wve) (Wave Life Sciences Ltd.): 4 buys totaling $54.6M — Director RA CAPITAL MANAGEMENT, L.P. at $6.06/share - [MLYS](/company/mlys) (Mineralys Therapeutics, Inc.): 2 buys totaling $8.8M — Director RA CAPITAL MANAGEMENT, L.P. at $23.67/share - [ZBIO](/company/zbio) (Zenas BioPharma, Inc.): 4 buys totaling $5.5M — Director Fairmount Funds Management LLC at $20.00/share - [AHCO](/company/ahco) (AdaptHealth Corp.): 2 buys totaling $4.4M — 10% Owner OEP VII GP, L.L.C. at $9.91/share - [IMNM](/company/imnm) (Immunome Inc.): 1 buy totaling $501K — President and CEO SIEGALL CLAY B at $19.67/share - [LENZ](/company/lenz) (LENZ Therapeutics, Inc.): 3 buys totaling $366K — President, CEO and Secretary Schimmelpennink Evert B. at $8.95/share - [XLO](/company/xlo) (Xilio Therapeutics, Inc.): 1 buy totaling $44K — Director Shannon James Samuel at $8.79/share - [DYN](/company/dyn) (Dyne Therapeutics Inc.): 1 buy totaling $34K — Director Posner Brian S at $17.08/share - [RZLT](/company/rzlt) (Rezolute, Inc.): 1 buy totaling $29K — CFO Evans Daron at $2.85/share - [CRIS](/company/cris) (CURIS INC): 1 buy totaling $5K — Director KAITIN KENNETH I at $0.55/share For the full list of filtered insider trades, see the insider signals page.

Not all insider purchases are equal. The strongest signals come from: 1. C-suite executives (CEO, CFO, CMO) rather than 10% institutional owners 2. Open-market purchases rather than option exercises or plan-based transactions 3. Dollar amounts that are material relative to the insider's compensation 4. Timing near catalysts (PDUFA dates, readout windows) where the insider has informational advantage 5. Cluster buys where multiple insiders at the same company buy within a short window BiotechEdge automatically classifies insider transactions and filters out noise so you see only the conviction-driven buys. See our research on Form 4 insider trading for the academic evidence behind this approach. *This article is generated from SEC EDGAR Form 4 filings and does not constitute investment advice.*